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Edited by Gianni CesareniAbstract Visfatin was originally identiﬁed as a growth factor
for immature B cells, and recently demonstrated to bind insulin
receptor. Visfatin mRNA and protein were detected by RT-
PCR and Western blot analysis in cloned bovine mammary epi-
thelial cells, lactating bovine mammary gland and human breast
cancer cell line, MCF-7. Immunocytochemical staining localized
the visfatin protein in the cytosol and nucleus of both cells.
Quantitative-RT-PCR analysis revealed that the expression of
the visfatin mRNA was signiﬁcantly elevated when treated with
forskolin (500 lM), isopreterenol (1–10 lM) and dibutyric cyclic
AMP (1 mM) for 24 h, and signiﬁcantly reduced when treated
with insulin (5–50 ng/ml) and dexsamethasone (0.5–250 nM) for
24 h. These results indicate that mammary epithelial cells
express the visfatin protein and secrete them into the milk.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Visfatin was ﬁrst isolated from the peripheral blood lympho-
cyte and characterized as a growth factor of premature B cells
[1]. It synergizes interleukin 7 (IL7) and stem cell factor to
facilitate the development of early stage B cells, and thus
named pre-B cell colony-enhancing factor (PBEF) [1,2]. Re-
cently, Fukuhara et al. [3] have demonstrated that visfatin ex-
erted insulin-mimicking eﬀects via binding and activation of
the insulin receptor in cultured 3T3-L1 adipocytes, H4IIEC3
hepatocytes and L6 myocytes cells, and lowered plasmaAbbreviations: bMEC, bovine mammary epithelilal cells; IL7, inter-
leukin 7; PBEF, pre-B cell colony-enhancing factor; cAMP, cyclic
AMP; Nampt, Nicotinamide phosphoribosyltransferase; NAD+, nic-
otinamide adenine dinucleotide; Sir, silent information regulator;
ERK1/2, extracellular signal-regulated kinase 1/2; NAPRTase, nico-
tinate phosphoribosyltransferase; CREBP, cAMP response element
DNA-binding protein; CREB, cAMP response element-binding pro-
tein; HRP, horseradish peroxidase
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doi:10.1016/j.febslet.2006.11.014glucose levels in mice. More recently, Revollo et al. [4] have
demonstrated that visfatin/PBEF possesses nicotinamide phos-
phoribosyltransferase (Nampt) activity, which is the rate-limit-
ing enzyme in the nicotinamide adenine dinucleotide (NAD+)
biosynthesis pathway and regulates the mammalian ortholog
Sirt1 of the NAD+ dependent silent information regulator
(Sir) 2 deacetylase. Despite its known multi-functional proper-
ties, the physiological signiﬁcance of visfatin still remains
unclear.
Visfatin is reported to be expressed in doxorubicin-respon-
sive breast cancer [5]. Bae et al. [6] have demonstrated that
hypoxia induced upregulation of visfatin mRNA and protein
inMCF-7 breast cancer cells. The above data suggest that visfa-
tin plays some important role in the mammary epithelial cells.
In 3T3-L1 adipocytes, isopreterenol and forskolin signiﬁ-
cantly suppressed the expression of visfatin mRNA [7], sug-
gesting that the visfatin mRNA expression may be regulated
via cyclic AMP (cAMP) pathway. On the other hand, dexa-
methasone, but not insulin, increased the expression of visfatin
mRNA [7]. In human subcutaneous adipocytes, insulin signif-
icantly suppressed the expression and the secretion of visfatin
[8].
Oxytocin plays a critical role for ejection of milk via contrac-
tion of myoepithelial cells in mammary gland [9]. However,
oxytocin receptor was reported to be expressed in non-lactat-
ing and lactating humans and marmosets [10]. Lollivier et al.
have demonstrated that oxytocin rapidly stimulates the secre-
tory process of caseins and proteins in rat and rabbit mam-
mary epithelial cells [11]. In breast cancer, oxytocin inhibited
the cell proliferation via increase of intra cellular cAMP con-
tent [12].
In this study, we demonstrated that the cloned bovine mam-
mary epithelial cells (bMEC), the human breast cancer cell line
MCF-7, and bovine lactating mammary gland expresses visfa-
tin mRNA and protein, and that visfatin protein is also present
in bovine milk. We also investigated whether or not visfatin
mRNA is induced by the activators of cAMP pathway or cer-
tain hormones.2. Materials and methods
2.1. Materials
MCF-7 cells were kindly provided by the Cell Resource Center for
Biomedical Research, Tohoku University (Sendai, Japan). Dulbecco’s
modiﬁed Eagle’s medium (DMEM), fetal calf serum (FCS), second-
ary ﬂuorescein isothiocyanate (FITC)-conjugated anti- rabbit IgG,blished by Elsevier B.V. All rights reserved.
6636 T. Yonezawa et al. / FEBS Letters 580 (2006) 6635–6643isoproterenol, forskolin, dibutylyl cAMP sodium salt, insulin, dexa-
methasone, oxytocin, atosiban and fraction V fatty acid-free bovine
serum albumin (BSA) were purchased from Sigma (St. Louis, MO,
USA). Skim milk was purchased from Wako (Osaka, Japan). TRIzol
and the SuperScript III First-Strand Synthesis System were obtained
from Invitrogen Corp. (Carlsbad, CA, USA), and the DyNAmo
SYBR green qPCR Kit was obtained from Finnzymes (Espoo, Fin-
land). Deoxyribonuclease (RT Grade) for Heat Stop was purchased
from the Nippon Gene Co., Ltd. (Tokyo, Japan). KOD plus DNA
polymerase was obtained from Toyobo Co., Ltd. (Osaka, Japan)
and the BCA protein kit was purchased from Pierce (Rockford, IL,
USA). The following antibodies were obtained from Cell Signaling
Technology Inc. (Beverly, MA, USA): rabbit anti-phospho Akt, rabbit
anti-Akt, rabbit anti-phospho extracellular signal-regulated kinase 1/2
(ERK1/2), and rabbit anti-ERK1/2 polyclonal antibodies. Secondary
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG was pur-
chased from Kirkegaard and Perry Laboratories Inc. (Gaithersburg,
MD, USA). Aﬃnity puriﬁed rabbit anti-human PBEF (BL2122) poly-
clonal antibody and blocking peptides for the polyclonal antibody
PBEF (BP2122) were purchased from Bethyl Laboratories Inc. (Mont-
gomery, USA). Microcon-10 ﬁlter was purchased from Millipore
Corp. (Berillerica, MD, USA). Recombinant human PBEF (ALX-
201-319-C050) was purchased from Alexis Corp. (Lausen, Switzer-
land). Human Visfatin ELISA kit and Visfatin C-terminal (Human)
EIA kit were purchased from AdipoGen Inc. (Seoul, Korea) and Phoe-
nix Pharmaceuticals, Inc. (CA, USA), respectively.
2.2. Cell cultures
bMEC were isolated from the mammary gland of a 102-day preg-
nant Holstein heifer and cloned using the limiting dilution method
[13]. FACS analysis revealed that all the cells were positively stained
using anti-cytokeratin antibody. Additionally, the cells possessed the
potential to produce a milk protein, alpha-casein, which is dependent
on the presence of lactogenic hormone cocktails [13]. bMEC and
MCF-7 cells were seeded at 1 · 104 cells/cm2 in a collagen coated 6-well
plate and 100-mm dish (Corning, NY) and grown in DMEM supple-
mented with 10% FCS, 2 mM glutamine, 100 units/ml penicillin, and
100 lg/ml streptomycin under 5% CO2 at 37 C until conﬂuent. The
cells were subjected to serum-deprivation overnight, and subsequently
treated for 24 h with a deﬁned concentration of a given hormone or
drug. Treatment of oxytocin was preceded by the treatment of atosi-
ban in some cells. Supernatant of the cells treated with oxytocin and/
or atosiban was collected. We then carried out the experiments accord-
ing to the procedures described below.2.3. Animals
All animals were handled in accordance with the ‘Guiding Principles
for the Care and Use of Animals in the Field of Physiological Sciences’
(Physiological Society of Japan). All experiments involving animals in
this study were approved by the Animal Care Committee of the Toho-
ku University. Three non-pregnant Holstein heifers and nine Holstein
dairy cows at various stages of the production cycle were used in this
study. The nine cows were at the following stages: peak lactation (PL:
n = 3), two months after parturition; late lactation (LL: n = 3), eight
months after parturition; and dry (DO: n = 3), three years after partu-
rition. The tissue samples were immediately placed in polypropylene
containers, frozen in liquid nitrogen, and stored at 80C until further
use.2.4. RNA preparation and RT-PCR analysis
The principal methods for total RNA extraction and RT-PCR were
described in our previous paper [14]. RT-PCR primers for the human
and bovine visfatin were designed from the visfatin mRNA sequences
(Accession Nos. NM_005746 and XM_878509). The sequence of the
primers are as follows: human visfatin forward, 5 0-TCAGTGCCTG
TATCTGTGGT-3 0; human visfatin reverse, 5 0-GATCAGCAACTG
GGTCCTTG-3 0; bovine visfatin forward, 5 0-CCTGAGGGCTCTGT
CATTCC-3 0; and bovine visfatin reverse, 5 0-GCCGCTGGTACAG
AATAGCC-3 0. The expected amplicon sizes for the human visfatin
and bovine visfatin were 451 and 377 bp, respectively. The PCR was
performed using the KOD plus DNA polymerase and 1 ll of the RT
product as template. Forty PCR cycles were carried out using the fol-
lowing cycling conditions: 15 s denaturation at 94 C, 30 s annealing at
52 C (for human) or at 53 C (for bovine), and 1 min extension at68 C. The DNA product was subcloned into a sequencing vector
and the DNA insert was sequenced to conﬁrm the identity of the
human and bovine visfatins. Human GAPDH speciﬁc PCR primer
set was purchased from Continental Laboratory Products Incorporated
(San Diego, CA, USA), and the PCR was carried out using the condi-
tions suggested by the manufacturer for a total of 40 cycles. RT-PCR
primers for the bovine GAPDH were used as described previously [15].2.5. Quantitative RT-PCR analysis
RT products were prepared as described previously [14]. Primers were
designed based on the bovine visfatin and GAPDHmRNAs (Accession
Nos. XM_878509 and U85042, respectively). Primers were designed
from human visfatin mRNA (Accession No. NM_005746). Primers
for the human GAPDH were used described previously [14]. Quantita-
tive RT-PCR was performed using a SYBR Green qPCR kit and the
DNA Engine Opticon 2 Continuous Fluorescence Detector (MJ
Research Inc, MA, USA), and using the following three sets of primers:
bovine visfatin forward, 5 0-CAGATCCGGAGTGTTACTGG-30
and bovine visfatin reverse, 5 0-CCTATGCCAGCAGTCTCTTG-3 0;
bovine GAPDH forward, 5 0-TCAACGGGAAGCTCACTGG-3 0 and
bovine GAPDH reverse, 5 0-CCCCAGCATCGAAGGTAGA-3 0;
human visfatin forward, 5 0-TCCAATCACAGTGGCCACAA-3 0 and
human visfatin reverse, 5 0-GATGCTCCTATGCCAGCAGT-30. The
expected amplicon sizes for the bovine visfatin and GAPDH and
human visfatin were 211, 225 and 156 bp, respectively. The PCRs were
performed as described previously [14]. The PCR was carried out for
40 cycles using the following protocol: 10 s denaturation at 95 C;
20 s annealing at 60 C; and 20 s extension at 72 C. Post-PCR melting
curves conﬁrmed the speciﬁcity of the single-target ampliﬁcation.
Expression of each gene relative to GAPDH was determined in tripli-
cate.2.6. Immunocytochemical staining
The cells were seeded in sonic seal slide wells (Nunc) and grown up
in DMEM supplemented with 10% FCS until 70–80% conﬂuent. The
cells were ﬁxed with 2% paraformaldehyde for 20 min, treated with
0.3% Triton X-100 for 10 min, blocked with 3% goat serum in PBS
for 1 h, and then incubated for 1 h with rabbit anti-human visfatin
antibody (1:200 dilution) in PBS containing 3% goat serum. The
unbound antibody was removed by washing 5 times with ice-cold
PBS, washed cells were incubated at room temperature for 1 h with
FITC-labeled anti-rabbit IgG (1:400 dilution) in PBS containing 3%
goat serum, and then counterstained with propidium iodide (PI). To
investigate the speciﬁcity of visfatin, the anti-visfatin antibody was pre-
absorbed with 10 lg blocking peptide. The cells were observed under a
ﬂuorescence microscope (Carl Zeiss Co., Ltd., Heidelberg, Germany).2.7. Milk and culture supernatant sample preparation
Milk samples were collected from ﬁve Holstein cows for 2 months
after parturition at Iwate Agricultural Research Center. Preparation
of milk samples for Western blot analysis was performed as described
previously [16]. In brief, milk samples (1.5 ml) were placed in 2 ml
tubes, 0.125 ml of 1.0 M HCl added to precipitate caseins, centrifuged
for 5 min at 3500 · g to remove the precipitated caseins, and the super-
natant was dialyzed for about 4 h against 1:10 diluted TBS (Tris-buf-
ferd saline) diluted with puriﬁed water; 0.2 M, pH 7.5, and using a
microcon-10 (a 10000 molecular weight cutoﬀ membrane). Additional
milk samples were centrifuged at 3500 · g, and dialyzed as described
above. Dialyzed samples were lyophilized. Lyophilized milk samples
were dissolved in 100 lL SDS loading buﬀer and boiled for 5 min
before subjecting to SDS–PAGE. Supernatant (10 ll) from the cells
was mixed with 5 ll of 3· Laemmli buﬀer and boiled to denature
proteins.2.8. Western blot analysis
After stimulation of the cells with recombinant human visfatin,
extraction and quantiﬁcation of total cellular proteins was performed
using a Nuclear Extraction Kit (Active Motif Inc., Carlsbad, CA,
USA). Equal amounts of cellular protein samples (40 lg/lane), culture
supernatant (overnight culture) or milk samples, as prepared above,
were subjected to 12.5% SDS–PAGE before being transferred to poly-
vinylidene diﬂuoride (PVDF) membranes. The membranes were ﬁrst
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Tween-20 (TBST) at room temperature for 1 h, after which they were
incubated overnight at 4 C with one of the following primary poly-
clonal antibodies (1:1000 dilution): anti-phospho Akt, anti-Akt, anti-
phospho ERK1/2, anti-ERK1/2, or anti-human visfatin antibody. To
investigate the speciﬁcity of visfatin, the anti-visfatin antibody was pre-
absorbed with 10 lg blocking peptide. The membranes were then
washed three times with TBST, followed by incubation at room tem-
perature for 1 h with the HRP-conjugated anti-rabbit IgG. secondary
antibody (1:10000 dilution). The membranes were then washed six
times with TBST and were visualized using an ECL+plus Western
Blotting Detection System (Amersham Pharmacia Biotech, Piscata-
way, NY).2.9. Measurement of secreted visfatin proteins
Supernatant visfatin content was measured using enzyme immuno-
assay (EIA) and enzyme-linked immunosorbent assay (ELISA),
according to manufacturer’s instructions. EIA has an intra- and in-
ter-assay coeﬃcients of variations were less than 5% and 14% and a
sensitivity of 2.83 ng/ml. ELISA has an intra- and inter-assay coeﬃ-
cients of variations were less than 5% and 10% and a sensitivity of
0.602 ng/ml.mouse
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Fig. 1. Amino acid sequence alignment (ClustalW) of indicated species of
asterisks (*). Epitope of anti-human visfatin polyclonal antibody, which was2.10. Statistical analysis
Values are expressed as the means ± S.E.M. of at least triplicate
samples in each experimental group; experiments were replicated to
ensure consistency. Statistical signiﬁcance was determined using a
one-way ANOVA followed by Bonferroni’s multiple range test.
Values were considered to be statistically signiﬁcant if their P value
was <0.05.3. Results
3.1. Identiﬁcation of bovine visfatin
We have identiﬁed a candidate for the bovine ortholog of
visfatin (Accession No. XM_878509) by performing similarity
searches of the public sequence databases using the human
visfatin sequence. As shown in Fig. 1A, the amino acid
sequence of the bovine visfatin was calculated to be 98% iden-
tical to pig visfatin (Accession No. DQ001974), 98% to mouse
visfatin (Accession No. NM_021524), 97% to rat visfatin
(Accession No. NM_177928), and 96% to human visfatinvisfatin. Amino acids conserved among all species are marked with
used in this study, is identical to bovine amino acids (shown in red).
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motifs of bovine visfatin using Pfam and SMART predicted
that the bovine candidate belongs to the nicotinate phospho-
rybosyltransferase (NAPRTase) family.
3.2. Expression of visfatin in mammary epithelial cells
Expression of visfatin mRNA in MCF-7 cells, bMEC and
bovine lactating mammary gland (Peak lactation) were evalu-
ated by RT-PCR analysis using speciﬁc primers and an ampli-
ﬁed DNA fragment of the expected size (Fig. 2A left lane in
each panel) was detected in each sample. No PCR product
was however detected in the absence of reverse transcriptase
(Fig. 2A right lane in each panel). The PCR product was
cloned, and the nucleotide sequence analysis of the cloned
fragment showed 100% sequence homology with the human
and bovine visfatin mRNAs. Bovine GAPDH primers
designed to amplify products from both genomic DNA
(458 bp) and cDNA (237 bp) produced only a single 237 bp
product, indicating that there was no contamination of geno-Visfatin
GAPDH
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Fig. 2. (A) Visfatin mRNA expression in MCF-7 cells (left panel),
bMEC (middle panel) and bovine lactating mammary gland (Peak
lactation) (right panel). RT-PCR was performed as described in
Section 2. The products were run on a 2% agarose gel stained with
ethidium bromide. To exclude ampliﬁcation from genomic DNA
contamination, the RNA was either treated with DNase before the RT
reaction (RT+) or run without RT (negative control, RT). A 100 bp
DNA step-ladder appears in the left lane as a molecular size marker.
(B) Visfatin protein expression in MCF-7 cells (right panel), bMEC
(right panel) and bovine lactating mammary gland (left panel). The
cells or tissue samples were analyzed by immunoblotting using anti-
human visfatin antibody. To investigate the speciﬁcity of visfatin, the
anti-visfatin antibody was preabsorbed with (Blocking peptides+) or
without (Blocking peptides) 10 lg blocking peptide. The ﬁgure shows
the data obtained from a representative experiment that was carried
out in triplicate.mic DNA (Fig. 2A, left lane). Expression of the visfatin
mRNA was detected throughout all stages of lactation (Sup-
plementary data A). The expression levels of the bovine visfa-
tin mRNA in various stages of lactating mammary gland were
quantiﬁed using quantitative-RT-PCR, but no signiﬁcant
change in the expression level was observed (Supplementary
data B). Western blot analysis using the antibodies raised
against a peptide corresponding to a conserved region between
the human and bovine visfatin (residues 400–450 in Fig. 1,
highlighted in red) revealed a single immunoreactive band at
approximately 52-kDa (corresponding to the visfatin protein)
in MCF-7 and bMEC (Fig. 2B). We also detected the 52-
kDa immunoreactive visfatin protein band in bovine lactating
mammary gland (Fig. 2B). Preabsorption of the anti-visfatin
antibody by the blocking peptides abolished the immunoreac-
tive band in all three samples (Fig. 2B). Because visfatin exerts
insulin-mimetic eﬀect by binding to the insulin receptor [3], we
examined whether ERK1/2 and Akt, proteins involved in insu-
lin signaling pathway, were phosphorylated in bMEC treated
with recombinant human visfatin. We were, however, unable
to observe phosphorylation of ERK1/2 and Akt in Western
blot analysis using the anti-phospho ERK1/2 and anti-phos-
pho Akt antibodies (Supplementary data C).
3.3. Subcellular localization of visfatin
We used immunocytochemistry to examine the subcellular
localization of the visfatin protein in MCF-7 and bMEC. We
found visfatin-speciﬁc immunoreactive signal in the cytoplasm
and nucleus of both cells (Fig. 3 middle panels). Preabsorption
of the anti-visfatin antibody by the blocking peptides abro-
gated the immunoreactive signal in both cells (Fig. 3 right pan-
els). In both cells, the immunoreactive signal was much
stronger in the nucleus than in the cytoplasm.
3.4. Presence of visfatin in milk
In order to examine whether or not visfatin protein exists in
the milk, Western blot analysis was performed on bovine milk
samples. We detected immunoreactive protein corresponding
to visfatin in both acid-treated and untreated bovine milk sam-
ples (Fig. 4). Preabsorption of the anti-visfatin antibody by the
blocking peptides abolished the immunoreactive band in bo-
vine milk samples (Fig. 4). Acid treated milk samples produced
enhanced immunoreactive signal due to the removal of caseins.3.5. Increase of cytosolic cyclic AMP concentration induce
upregulation of visfatin mRNA
In order to determine whether or not elevation of cellular
cAMP concentration increases visfatin mRNA in bMEC,
we examined the eﬀects of forskolin, isopreterenol and dibuty-
ryl cAMP on the expression of visfatin mRNA by quantita-
tive-RT-PCR. Incubation of cells with 500 lM forskolin
(Fig. 5A), 1–10 lM isopreterenol (Fig. 5B) or 1 mM dibutylyl
cAMP (Fig. 5C) for 24 h signiﬁcantly increased the expression
of the visfatin mRNA. We also observed isopreterenol concen-
tration-dependent (in the 1–5 lM range) increase in the visfa-
tin mRNA expression (Fig. 5B).3.6. Insulin and dexamethasone decrease visfatin mRNA
expression
We used quantitative-RT-PCR to examine the eﬀects of
the hormones insulin, dexamethasone, and bovine growth
Fig. 3. Subcellular localization of visfatin protein in MCF-7 and bMEC. Both MCF-7 cells (upper panels, Bar = 50 lm) and bMEC (lower panels,
Bar = 100 lm) were stained by means of indirect immunoﬂuorescence with antibodies against human visfatin, as described in Section 2. The cell
nuclei were stained with propidiumiodide (PI). To investigate the speciﬁcity of visfatin, the anti-visfatin antibody was preabsorbed with
(Preabsorption) or without (Visfatin) 10 lg blocking peptide. The cells were stained only by FITC-conjugated secondary antibody (Negative control).
200kDa
125kDa
60kDa
32kDa
Milk
Blocking peptide +-
Milk
+-
Acid precipitation+ -
Fig. 4. Visfatin protein exists in bovine milk. Milk samples were
analyzed by immunoblotting using ani-human visfatin antibody. To
investigate the speciﬁcity of visfatin, the anti-visfatin antibody was
preabsorbed with (Blocking peptides+) or without (Blocking pep-
tides) 10 lg blocking peptide. Milk samples were treated with (Acid
precipitation+) or without (Acid precipitation) 1.0 M HCl. The
ﬁgure shows the data obtained from a representative experiment that
was carried out in triplicate.
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and investigated whether certain hormones would upregulate
the visfatin mRNA expression. Incubation of cells with 5–
50 ng/ml insulin (Fig. 6A) or 0.5–250 nM dexsamethasone
(Fig. 6B) for 24 h signiﬁcantly suppressed the expression of
the visfatin mRNA (Fig. 6A). Incubation of cells with 0.5–1000 ng/ml bovine GH had no eﬀect on the visfatin mRNA
expression (data not shown).
3.7. Oxytocine decrease visfatin mRNA expression and protein
secretion
Finally, we examined the eﬀects of oxytocin on visfatin
mRNA expression and protein secretion. Incubation of cells
with 500 nM oxytocin for 24 h signiﬁcantly suppressed the
expression of the visfatin mRNA expression in bMEC
(Fig. 7A), which was partially blocked by pre-treatment with
100 pg/ml atosiban which is a functional oxytosin antagonist
(Fig. 7B). We determined the levels of secreted visfatin protein
into culture media using western blot analysis. Incubation of
the cells with 500 nM oxytocin for 24 h signiﬁcantly decreased
the levels of visfatin protein, which was partially blocked by
pre-treatment with atosiban (Fig. 7C). In MCF-7, 0.5–
1000 nM oxytocin did not change the expression of visfatin
mRNA (Supplementary data D). ELISA assay revealed that
the levels of secreted visfatin protein also did not signiﬁcantly
change by the treatment of oxytocin (Supplementary data E).
Similar result was obtained by EIA assay (data not shown).
However, both two cells secreted substantial amount of visfa-
tin protein into culture media.4. Discussion
Our results showed for the ﬁrst time that the visfatin mRNA
and protein are expressed in cloned bMEC and lactating mam-
mary gland. We also detected the visfatin mRNA and protein
in MCF-7 cells, which is consistent with the previous report [6].
In both bMEC and MCF-7 cells, subcellular localization of
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atin is present more abundantly in the cellular nuclei than in
the cytoplasm. Kitani et al. previously demonstrated that the
visfatin protein was more abundant in the cytoplasm than in
the nucleus of the proliferating PC-12 and Swiss 3T3 cells; in
contrast, the visfatin protein was found to be more abundant
in the nucleus than in the cytoplasm of the PC-12 cells treated
with nerve growth factor and 3T3 cells grown to a conﬂuent
state [17]. Our results are similar to those found in the nerve
growth factor-treated PC-12 cells and conﬂuent 3T3 cells as
mentioned above. We have for the ﬁrst time demonstrated that
the visfatin protein exists in bovine milk. We also detected sub-
stantial amount of visfatin protein in culture supernatant from
both MCF-7 and bMEC cells. These data suggest that visfatin
may play some important role in mammary epithelial cells and
mammary gland, and that the secretory epithelial cells may be
the source of visfatin in milk. We hypothesize that the milk
visfatin may be important for the neonates in the same manner
as leptin [18], although it is not known whether this protein
directly or indirectly induces physiological eﬀect.
In 3T3-L1 cells, 200 lM forskolin and 10 lM isopreterenol
suppressed the expression of visfatin mRNA [7]. Our results,
on the other hand, showed that 500 lM forskolin, 1–10 lM
isopreterenol and 1 mM dibutylyl cAMP induced upregulationof the visfatin mRNA. Using the computer database PAGen@
UIC (http://www.uic.edu/pharmacy/depts/pmpcpd/pagen/) or
TRANSFAC (http://motif.genome.jp/), we have screened the
5 0-ﬂanking regions of the human, mouse and bovine visfatin
genes (between positions 2249 and +1 for the human and
mouse and between positions 342244 and 344493 for the
bovine in NW_931289) for putative cAMP response element
DNA-binding protein 1 (CREBP 1) and cAMP response
element-binding protein (CREB) sites. Our results are summa-
rized in Table 1. Previously, it was shown that in 3T3-L1 adi-
pocytes, isopreterenol and forskolin signiﬁcantly suppressed
the expression of visfatin mRNA [7]. Taken together, these
data suggest that cellular cAMP regulates the expression of
the visfatin mRNA in adipocytes and mammary epithelial cells
in opposite manner. The transcription factor CREB regulates
numerous cellular processes. Hypoxia, which is known to
upregulate visfatin mRNA expression in MCF-7 [6], also acti-
vates CREB via phosphorylation [19–21]. Thus, elevation of
the cellular cAMP concentration might have similar eﬀect as
hypoxia, resulting in upregulation of the visfatin mRNA.
Unexpectedly, we could not observe the induction of visfatin
Table 1
The number of putative CREBP 1 and CREB in 5 0-franking region of
indicated species visfatin gene
Species Number Position Sequence
Putative CREBP1
Human 1 1590–1597 ttaggtaa
Mouse 0 546–553 ttaagtaa
Cow 2 1310–1317 ttacgcaa
Putative CREB
Human 4 572–579 tgacttca
935–942 tgaagtca
945–952 agacgtca
1440–1447 tgacttca
Mouse 2 1075–1082 tgacgtca
1085–1092 agacgtca
Cow 3 213–220 tgacttca
1367-1374 tgaagtca
1866-1873 tgacttca
T. Yonezawa et al. / FEBS Letters 580 (2006) 6635–6643 6641mRNA and protein secretion by treatment of oxytocin in both
bMEC and MCF-7 cells. However, Cassoni et al. hypothesized
that since the increase in cAMP levels was slow, the eﬀect of
oxytocin may be indirected modulation of this second messen-
ger by other still unidentiﬁed signaling pathway in breast can-
cer cells [12]. In the near future, further studies may reveal a
physiological activator of visfatin via increase of intracellular
cAMP concentration in mammary epithelial cells.
In various cell types, visfatin exerts insulin-mimetic eﬀect by
binding to the insulin receptor [3]. In bMEC treated with
recombinant human visfatin, we failed to observe any phos-
phorylation of the ERK1/2 and Akt, which are insulin-signal-
ing molecules. However, physiological concentration of insulin
(5–10 ng/ml) induced down-regulation of the visfsatin mRNA,
suggesting that the insulin-mimetic eﬀect may be negatively
regulated by the activation of the insulin signaling in bMEC.
In human subcutaneous adipocyte, insulin decreased the
expression and the secretion of visfatin [8], which was consis-
tence with our result.0
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Fig. 7. Eﬀects of oxytocin on the expression of visfatin mRNA and the
secretion of visfatin protein in bMEC. Serum-starved cells were treated
with 0.5–1000 nM oxytocin (A) with or without 100 pg/ml atosiban (B)
for 24 h. The cDNA produced by reverse transcription from 5 lg of
bMEC total RNA was analyzed by quantitative-RT-PCR. The relative
values of visfatin to GAPDH mRNA are shown. The data are
expressed as the means ± S.E.M. (n = 3). (C) Visfatin protein expres-
sion in bMEC. Supernatants from serum-starved cells were treated
with 500 nM oxytocin with or without 100 pg/ml atosiban for 24 h
were analyzed by immunoblotting using anti-human visfatin antibody
(upper panel). The intensity of the bands was analyzed using NIH
image software and given in relative units. The data are expressed as
the means ± S.E.M. (n = 3). The ﬁgure shows the data obtained from a
representative experiment that was carried out in triplicate. The values
labeled using the same letter are not signiﬁcantly diﬀerent, whereas the
values labeled using diﬀerent letters are signiﬁcantly diﬀerent (P < 0.05,
Bonferroni’s multiple range test).Our results showed that in bMEC dexamethasone (0.5–
250 nM) suppressed the expression of the visfatin mRNA. In
3T3-L1 adipocytes, dexamethasone however increased the
expression of the visfatin mRNA [7]. Glucocorticoids are
known to activate pro-apoptotic [22] and anti-apoptotic [23–
26] signaling in various type cells. Sir2, which is a NAD+
dependent-protein deacetylase [4], plays important role in gene
silencing [27], cell cycle regulation [28] and life span extension
[29,30]. Sir2 also negatively regulates the tumor suppressing
transcriptional factor p53, which plays an important role in
cellular response to host cellular stress conditions [31,32].
Taken together, our results suggest that the dexametasone-in-
duced stress condition may activate the p53 pathway, resulting
in suppression of the NAD+ biosynthesis by visfatin.
In conclusion, our results revealed the presence of visfatin
mRNA and protein in MCF-7 cells, bMEC and lactating
mammary gland. We also demonstrated its regulation by the
cAMP pathway, insulin and dexamethasone, suggesting that
visfatin plays an important role in mammary epithelial cells.
We have for the ﬁrst time demonstrated the presence of the
visfatin protein in bovine milk, suggesting that the secretory
epithelial cells may be the source of visfatin in the milk.
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Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.febslet.2006.11.014. Sup-
plementary data. (A) Visfatin mRNA expression in various
stages of bovine lactating mammary gland. RT-PCR was per-
formed as described in Section 2. The products were run on a
2% agarose gel stained with ethidium bromide. A 100 bp
DNA ladder appears in the left lane as a molecular size marker.
The ﬁgure showed the amplicons of visfatin (upper panel) or
6642 T. Yonezawa et al. / FEBS Letters 580 (2006) 6635–6643GAPDH (lower panel) in indicated stages of bovine mammary
gland. (B) The cDNA produced by reverse transcription from
5 lg of total RNA, extracted from various stages of bovine lac-
tating mammary gland, were analyzed by quantitative-RT-
PCR. The data are expressed as the means ± S.E.M. (n = 3).
(C) Eﬀects of human recombinant visfatin on the phosphoryla-
tion of ERK1/2 and Akt. Cells were stimulated with 100 ng/ml
human recombinant visfatin for the indicated times. Cell lysates
were analyzed by immunoblotting using an antibody that was
phospho-speciﬁc or speciﬁc for total Akt (upper panels) or
ERK1/2 (lower panels). (D) Eﬀects of oxytocin on the expres-
sion of visfatin mRNA in MCF-7. Serum-starved cells were
treated with 0.5–1000 nM oxytocin for 24 h. The cDNA pro-
duced by reverse transcription from 5 lg of MCF-7 total
RNA was analyzed by quantitative-RT-PCR. The relative val-
ues of visfatin to GAPDH mRNA are shown. The data are ex-
pressed as the means ± S.E.M. (n = 3). (E) Concentration of
visfatin protein in supernatant in MCF-7. Supernatants from
serum-starved cells were treated with 0.5–1000 nM oxytocin
for 24 h were analyzed by ELISA assay. The data are expressed
as the means ± S.E.M. (n = 3). Mean values labeled using the
same letter are not signiﬁcantly diﬀerent, whereas mean values
labeled using diﬀerent letters are signiﬁcantly diﬀerent
(P < 0.05, Bonferroni’s multiple range test).References
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